Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 119 clinical trials
Featured trial
Build 10 Formal Testing

Build 10 Formal Testing

  • 0 views
  • 19 Feb, 2024
Featured trial
Virtual Trial 01  

Test Comment here 

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 1 location
Featured trial
  • 0 views
  • 19 Mar, 2025
  • 1 location
Featured trial
test23  

uuu

Accepts healthy volunteers
  • 0 views
  • 18 Mar, 2025
  • 2 locations
Featured trial
T1-S1-US - Published Trial (Published Trial)  

T1-S1-US - Published

Accepts healthy volunteers
  • 0 views
  • 29 May, 2025
  • 1 location
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707)  

Primary Objectives:Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G)Define the Maximium …

  • 0 views
  • 04 Apr, 2025
  • 1 location
  • Online study
RJ_StudyVirtualF  

Acne

Online studies
  • 0 views
  • 19 Feb, 2024
  • 1 location
  • Online study
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

The present trial will be performed to characterize the dose-response curve for BI 655130 in patients with a history of Generalized Pustular Psoriasis (GPP, per European Rare and Severe Psoriasis Expert Network (ERASPEN) criteria) who are now (at screening and at randomization) presenting with a Generalized Pustular Psoriasis Physician Global …

  • 0 views
  • 19 Feb, 2024
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

  • 0 views
  • 04 Mar, 2025
Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy  

At present, the majority of studies on neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) use pathological complete response (pCR) as a surrogate marker for patient prognosis, with significant improvements in pCR indicating better long-term survival. However, there is still a lack of non-invasive tools for accurately predicting the …

  • 0 views
  • 11 Mar, 2025